Ava, a San Francisco, CA- and Zurich, Switzerland-based medical technology company focused on innovations in women’s reproductive health, raised $9.7m in Series A funding.
The round was led by European VC firm Polytech Ecosystem Ventures with participation from new investors Blue Ocean Ventures and Global Sources, existing investors Swisscom and ZKB, etc.
The company will use the funds for further product development, scale production of bracelets, and expansion into international markets.
Co-founded by Lea von Bidder and Pascal Koenig, Ava provides a bracelet which uses a patented big data approach to detect a woman’s entire fertile window in real time. the FDA-approved medical device works by recording nine physiological factors that correspond with the rise in hormones indicating the onset of ovulation. It was proven in a recently concluded clinical study at the University Hospital of Zurich to detect an average of 5.3 fertile days per cycle with 89% accuracy.
The company is now planning further clinical studies to expand its algorithms for use in both pregnancy recognition, pregnancy monitoring, and possible use as a non-hormonal contraceptive device.